

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Drug Use Review Board

Meeting Minutes

Date of Meeting: Thursday, April 28, 2022

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board

Agenda Item	Record	Notes																					
<p>1. Call to Order and Roll Call</p>	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Wheeler called the meeting to order at 1:06 p.m. on April 28, 2022.</p> <p>Chairperson Wheeler took the roll.</p> <table data-bbox="772 1122 1514 1408"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>The DHCFP Staff Present were as follows:</p> <p>Griffin, Karen, Senior Deputy Attorney General (SDAG)</p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist (SSPS) III</p> <p>Berntson, Kindra, SSPS II</p> <p>Alegria, Veronica, SSPS I</p> <p>Flowers, Ellen, Program Officer I</p>
	Present	Absent																					
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					
Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																					
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																					

Agenda Item	Record	Notes
	<p>Brian Le, DO <input type="checkbox"/> <input checked="" type="checkbox"/></p> <p>Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>A quorum was present.</p>	<p>Managed Care Organization representatives present were as follows: Lim, Luke, RPh, Anthem Blue Cross Crecco, Jason, Pharm.D., Health Plan of Nevada Tran, Jimmy, Pharm.D., Molina Healthcare Beranek, Tom, RPh, SilverSummit Health Plan</p> <p>Gainwell Technologies Staff Present were as follows: Leid, Jovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: LeCheminant, Jill, Pharm.D. Piccirilli, Annette Kiriakopoulos, Amanda, Pharm.D.</p> <p>The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.</p>
<p>2. General Public Comment</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p>	

Agenda Item	Record	Notes																																				
	<p>No public comment was provided.</p> <p>No written comment was received.</p>																																					
3. Administrative																																						
<p>a. For Possible Action: Review and Approve Meeting Minutes from January 27, 2022</p>	<p>No corrections were offered.</p> <p>Board Member Canty moved to approve the minutes as presented, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="772 699 1535 1024"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>b. Status Update by DHCFP</p>	<p>Chief David Olsen announced the start date of July 1, 2022, for Magellan Medicaid Administration as Nevada's new pharmacy benefit manager (PBM). He welcomed Dr. James Kim as the Nevada Account Pharmacy Services Director.</p> <p>Chief Olsen discussed that Senate Bill 325, which enables pharmacists to prescribe HIV preventative therapy, is expected to receive final approval. Chief Olsen noted the component of Senate Bill 325, which enables pharmacists to dispense oral contraceptive therapy without a prescription, has been completed. To enroll as a provider, continuing education for pharmacists is required. Nevada</p>																																					

Agenda Item	Record	Notes
	<p>pharmacist contraceptive services training program is now available at birthcontrolpharmacist.com.</p> <p>Mr. Antonio Gudino announced the changes from the October 2021 DUR meeting had been posted after a delay because of technical issues. He reminded the Board to remain on camera during the meeting and when voting. He asked members of the public to stay off the camera unless speaking during public comment.</p>	
<p>4. Clinical Presentations</p>		
<p>a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Movement Disorder Agents.</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Ms. Rochelle Yang with Teva Pharmaceuticals regarding Austedo. She provided information on two open-label extension trials for Austedo and guideline updates relative to movement disorder agents.</p> <p>No written comment was received.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Jill LeCheminant noted the mechanism of action and indications for two movement disorder medications: Austedo and Ingrezza. She reviewed the proposed criteria for both drugs and discussed the utilization of the medications in the class.</p> <p>Mr. Luke Lim proposed the criteria include safety-related exclusion criteria from the FDA label. He highlighted the utilization of Ingrezza.</p>	

Agenda Item	Record	Notes																																				
	<p>Dr. Jason Crecco agreed with the proposed criteria and noted Ingrezza as the highest used agent.</p> <p>Mr. Tom Beranek agreed with the proposed criteria and noted Austedo and Ingrezza utilization.</p> <p>Board Member Tran agreed with the proposed criteria.</p>																																					
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Board Member Canty discussed a motion to include the safety-related criteria suggested by Anthem. Board Member Adeolokun asked for clarification as to why the proposed criteria from Optum removed the safety-related criteria. Dr. LeCheminant explained the current criteria included safety-related requirements were removed to allow for less restrictive access, and the prescribing neurologist or psychiatrist would monitor safety-related concerns. The Board discussed the safety-related criteria.</p>																																					
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Adeolokun motioned to approve the Austedo criteria as presented by Optum.</p> <p>Board Member England seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="756 1088 1554 1412"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

Agenda Item	Record	Notes																																				
	<p>Board Member England motioned to approve the Ingrezza criteria as presented.</p> <p>Board Member Canty seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="772 483 1535 813"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Sedative Hypnotics.</p>																																						
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p> <p>No written comment was received.</p>																																					
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. LeCheminant discussed the new indication of Hetlioz to treat nighttime sleep disturbances in Smith-Magenis syndrome (SMS). Dr. LeCheminant reviewed the proposed criteria presented in the binder and discussed the utilization of Hetlioz.</p> <p>Mr. Lim agreed with the proposed criteria and noted no utilization.</p>																																					

Agenda Item	Record	Notes																																				
	<p>Dr. Crecco agreed with the proposed criteria and noted no utilization.</p> <p>Mr. Beranek agreed with the proposed criteria. He noted no utilization of Hetlioz.</p> <p>Board Member Tran proposed adding an age minimum of 18 years old.</p>																																					
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Board Member Castaneda asked why the proposed criteria included an age minimum of three years old. Dr. LeCheminant stated that is the age indication per the FDA label and confirmed a request could be submitted for patients under three years of age.</p>																																					
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Adeolokun moved to approve the criteria as presented.</p> <p>Board Member Canty seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="756 1015 1543 1347"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>c. For Possible Action: Discussion and possible adoption of prior</p>																																						

Agenda Item	Record	Notes
<p>authorization criteria and/or quantity limits for Monoclonal Antibodies for the Treatment of Respiratory Conditions.</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Comment was provided by Dr. Ben Droese from Amgen Medical Affairs regarding Tezspire. Dr. Droese commented on clinical trials showing efficacy. He discussed the clinical indication and Tezspire's novel approach to treating severe asthma. He requested Tezspire be added as a preferred treatment option.</p> <p>Written comment was received regarding Tezspire.</p> <p>Written comment was received regarding Dupixent requesting otolaryngologists be added as an acceptable prescriber specialty for the chronic rhinosinusitis with nasal polyps indication.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. LeCheminant proposed a name change for the title of the prior authorization from Respiratory Monoclonal Antibody Agents to Respiratory and Allergy Biologics. She noted the criteria include coverage for indications other than respiratory conditions.</p> <p>Dr. LeCheminant discussed the new indication of Xolair for the treatment of nasal polyps. She reviewed the proposed criteria presented in the binder and discussed the utilization of medications in this class.</p> <p>Mr. Lim agreed with the proposed criteria and noted Dupixent is, by far, the most used in this class.</p> <p>Dr. Crecco agreed with the proposed criteria and noted high utilization of Xolair.</p>	

Agenda Item	Record	Notes																																				
	<p>Mr. Beranek agreed with the proposed criteria. He noted the utilization of Xolair and Dupixent.</p> <p>Board Member Tran agreed with the Xolair proposed criteria. He noted suggested changes to criteria for other agents in this class.</p>																																					
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>The Board discussed the prescriber specialties for Dupixent criteria.</p>																																					
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Castaneda moved to add otolaryngologists to the prescriber specialties for Dupixent’s chronic rhinosinusitis with nasal polyps’ indication.</p> <p>Board Member England seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="756 841 1543 1177"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Adeolokun moved to accept the proposed name change to Respiratory and Allergy Biologics.</p> <p>Board Member England seconded the motion.</p> <p>A vote was held:</p>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

Agenda Item	Record	Notes																																																																								
	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Board Member Tran motioned to approve the Xolair criteria as presented.</p> <p>Board Member Sparks seconded the motion.</p> <p>A vote was held:</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Rebecca Sparks, PA-C</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																																																							
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
	Yes	No	Abst.																																																																							
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Rebecca Sparks, PA-C	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																																																							
<p>d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Vuity.</p>																																																																										
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p>																																																																									

Agenda Item	Record	Notes												
	<p>Comment was provided by Ms. Charlie Lovan from AbbVie for Vuity. She informed the Board she was available for any questions.</p> <p>No written comment was received.</p>													
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. LeCheminant discussed the drug Vuity, including the mechanism of action, indication, administration, and clinical trial showing efficacy. Dr. LeCheminant reviewed the proposed criteria presented in the binder and discussed the utilization of the Vuity.</p> <p>Mr. Lim agreed with the proposed criteria and reported no utilization for Vuity.</p> <p>Dr. Crecco agreed with the proposed criteria and noted no utilization.</p> <p>Mr. Beranek agreed with the proposed criteria and noted no utilization.</p> <p>Board Member Tran proposed an age minimum of 18 years of age be added to the criteria.</p>													
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>													
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Adeolokun motioned to approve the Vuity criteria as presented.</p> <p>Board Member Castaneda seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="756 1299 1533 1404"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

Agenda Item	Record	Notes
	Mark Canty, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Rebecca Sparks, PA-C <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	
5. DUR Board Requested Reports		
a. For Possible Action: Opioid utilization – top prescriber and members.		
i. Presentation of opioid criteria		
ii. Discussion by the Board and review of utilization data.	<p>Dr. LeCheminant presented the opioid utilization report. She summarized the opioid 12-month trend. Dr. LeCheminant discussed the patient diagnoses of the top utilizers, and those members being treated with opioids for cancer pain were excluded from the top utilizers. She noted prescribed morphine equivalent dosing (MED) of the top providers.</p> <p>Mr. Lim presented opioid utilization trends and identified a steady MED level. He discussed the top providers and top utilizers, noting the high use of methadone.</p> <p>Dr. Crecco presented opioid utilization trends. He noted a slight downward trend in opioid scripts and discussed the top prescribers, top members and how the two lists correlate.</p> <p>Mr. Beranek presented opioid utilization trends highlighting a decrease in utilization. He discussed the top 10 prescribers, noting little change from quarter to quarter.</p> <p>Board Member Castaneda expressed concern about the high opioid utilization. The Board discussed options to address high opioid</p>	

Agenda Item	Record	Notes
	utilization, including sending letters to the top prescribers and members. Chief Olsen shared a letter template as an option to notify providers. The Board discussed if they should exclude certain prescribers from receiving the letter, such as oncologists.	
iii. Requests for further evaluation of proposed clinical criteria to be presented at a later date.	The Board requested the letter template be provided for review and details of the top 10 prescribers be included in the reports.	
6. Standard DUR Reports		
a. Review of Prescribing/ Program Trends.		
i. Top 10 Therapeutic Classes for Q4 2021 (by Payment and by Claims).	<p>Dr. LeCheminant presented the top classes with similar results over the quarter, with hemostatic agents on the top by spend amount and anticonvulsants at the top by claim count.</p> <p>Mr. Lim presented the top classes and highlighted viral vaccines as the top class by claim count.</p> <p>Dr. Crecco presented the top classes and identified viral vaccines as the top class by claim count.</p> <p>Mr. Beranek presented the top drug classes and identified viral vaccines as the top class by claim count.</p>	
b. Concurrent Drug Utilization Review (CDUR).		
i. Review of Q4 2021. ii. Review of Top Encounters by Problem Type.	<p>Dr. LeCheminant highlighted the prospective DUR reports and the interventions.</p> <p>Mr. Lim discussed the prospective DUR and the interventions.</p> <p>Dr. Crecco pointed out the prospective DUR report and the interventions.</p>	

Agenda Item	Record	Notes
	Mr. Beranek pointed out the prospective DUR report and the interventions.	
c. Retrospective Drug Utilization Review (RetroDUR).		
<ul style="list-style-type: none"> i. Status of previous quarter. ii. Status of current quarter. iii. Review and discussion of responses. 	<p>Dr. LeCheminant discussed the retrospective DUR initiatives during the last quarter with members concurrently using an opioid, antipsychotic, and benzodiazepine.</p> <p>Mr. Lim highlighted the retrospective DUR programs, including diabetic monitoring and flu vaccination.</p> <p>Dr. Crecco discussed retrospective DUR initiatives and results, highlighting the gap in care initiatives for asthma, cardiovascular, and COPD.</p> <p>Mr. Beranek discussed the retrospective DUR program highlighting outreach to providers regarding dangerous three-drug combinations, respiratory overuse, MME benchmark, diabetic under-use, and antiepileptic adherence. He noted overall response rates.</p>	
7. Closing Discussion		
a. Public Comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>	
b. For Possible Action: Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for July 28, 2022.	
c. Adjournment.	The meeting adjourned at 2:44 p.m.	


Attachment A – Members of the Public in Attendance


Andrada, Alex, Optum
Angelcyk, Steve
Ashton, Elisa, JNJ
Bailey, Abigail, DHCFP
Belz, Jeanette, Belz & Case
Berry, Kenneth, Alkermes
Breen, Amy
De Rosa, Regina, WellPoint
Deason, John, Neurocrine
Delgado , Brenda, Novonordisk
Dickerson, Todd, Jazz Pharma
Droese, Ben, Amagen
Embra, Jason, Molina

Germain Jr., Joe, Biogen
Gonzales, Becky, ViiV
Hameline, William, MWE
Harrison, Emily, Molina
Hart, Tiffani, WellPoint
Hartman, Nena, Neurocrine
Hawkins, Tina, Magellan
Kim, James, Magellan
Kunke, Kenneth, Roseman
Lawrence, Henry, Fidelis Rx
Levin, MD, Amy, WellPoint
Lovan, Charlie, Abbvie
Mahoney, Cassandra, Roseman

Mishra, Rajendra, VA
Ou, Karen, Gilead
Pearson, Cinnamon, Pearson
Roa, Ryan, Merck
Sato, Samantha
Sullivan, Mike, Amagen
White, Rianna, Fidelis Rx
Williams, Jameca, Anthem
Yamashita, Kelvin
Yang, Rochelle, Teva
Zarob, Michael, Alkermes

Attachment B – Submitted Written Comment

 Dupixent Comment

 TEZSPIRE™ (tezepelumab-ekko) Clinical Fact Sheet